Short answer
Paysign, Inc. (PAYS) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $31M (up 42.6% year over year) with net income of $7M.
Q3 2026 key financials · XBRL
- Revenue
- $31M
- +42.6% YoY · +9.0% QoQ
- Net income
- $7M
- +204.1% YoY · −0.3% QoQ
- Operating margin
- 23.8%
- Gross margin
- 64.7%
- EPS (diluted)
- $0.10
- +233.3% YoY · −9.1% QoQ
Source: XBRL data from the Paysign, Inc. (PAYS) Q3 2026 10-Q on SEC EDGAR. USD.
Paysign, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $30.8M, up 42.6% YoY from $21.6M
- Pharma revenue $16.6M, up 109.8% YoY, strongest segment
- Other revenue $353K, down 56.7% YoY, weakest line
- Gross margin 64.7% vs 56.3%; net margin 21.9% vs 10.3% YoY
- Operating cash flow $82.8M; cash $34.5M, up $13.5M from December 31, 2025
- Headwind: plasma payment transition for 113 centers expected to reduce revenue and gross profit beginning Q4 2026 through 2027
Risk Factors
- Smaller reporting company exemption: no Item 1A risk-factor disclosure required in this 10-Q
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Paysign, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.